TD Waterhouse Canada’s Grace Therapeutics GRCE Stock Holding History

TD Waterhouse Canada’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$4	–	1811
2023 Q3	$4	Hold	1	–	–	﹤0.01%	1712
2023 Q2	$3	Hold	1	–	–	﹤0.01%	1755
2023 Q1	$2	Hold	1	–	–	﹤0.01%	1741
2022 Q4	$3	Hold	1	–	–	﹤0.01%	1700
2022 Q3	$3	Hold	1	–	–	﹤0.01%	1706
2022 Q2	$4	Buy	+1	New	+$6	﹤0.01%	1741

Other funds holding GRCE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

IGWM

ICA Group Wealth Management Denver, Colorado $167M AUM 18.57% 1-Year Est. Return

TD Waterhouse Canada's GRCE Position: Q4 2023 in Review

TD Waterhouse Canada sold out of Grace Therapeutics (GRCE) in Q4 2023, closing a stake of 1 share — an estimated $4 sold.

TD Waterhouse Canada first reported a position in GRCE in Q2 2022 and held it in 6 quarters. The position peaked at $4 in Q3 2023. 9 funds tracked by Wall St. Rank hold GRCE as of Q4 2023.

TD Waterhouse Canada reported no remaining Grace Therapeutics position as of Q4 2023 after selling out during the quarter.
TD Waterhouse Canada sold 1 Grace Therapeutics share in Q4 2023, an estimated $4.
TD Waterhouse Canada first reported a position in Grace Therapeutics in Q2 2022 and held it in 6 quarters.
TD Waterhouse Canada's Grace Therapeutics position peaked at $4 in Q3 2023.
9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2023.

Based on TD Waterhouse Canada's 13F filing for Q4 2023, filed 12 Feb 2024.